Generation Bio Co.

NasdaqGS:GBIO Rapport sur les actions

Capitalisation boursière : US$36.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Generation Bio Bilan de santé

Santé financière contrôle des critères 4/6

Generation Bio possède un total de capitaux propres de $50.6M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $121.9M et de $71.3M.

Informations clés

0%

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$89.62m
Fonds propresUS$50.56m
Total du passifUS$71.34m
Total des actifsUS$121.90m

Mises à jour récentes de la santé financière

Article d’analyse Nov 14

Companies Like Generation Bio (NASDAQ:GBIO) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse May 01

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d’analyse Dec 07

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d’analyse Jul 11

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Article d’analyse Mar 11

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Recent updates

Article d’analyse Nov 14

Companies Like Generation Bio (NASDAQ:GBIO) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse Jul 14

There Is A Reason Generation Bio Co.'s (NASDAQ:GBIO) Price Is Undemanding

With a price-to-sales (or "P/S") ratio of 1.1x Generation Bio Co. ( NASDAQ:GBIO ) may be sending very bullish signals...
Article d’analyse Mar 16

Generation Bio Co. (NASDAQ:GBIO) Not Doing Enough For Some Investors As Its Shares Slump 29%

Unfortunately for some shareholders, the Generation Bio Co. ( NASDAQ:GBIO ) share price has dived 29% in the last...
Article d’analyse May 01

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d’analyse Dec 07

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d’analyse Jul 11

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Article d’analyse Mar 11

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Article d’analyse Nov 19

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Article d’analyse Aug 05

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha Aug 04

Generation Bio GAAP EPS of -$0.66 misses by $0.04

Generation Bio press release (NASDAQ:GBIO): Q2 GAAP EPS of -$0.66 misses by $0.04. The company believes that its cash position of $312.2M will fund its operating plan into 2025. “We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progress in establishing the proprietary technologies necessary to realize our vision,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “This quarter, process development and scaling of rapid enzymatic synthesis (RES) for production of our closed-ended DNA (ceDNA) construct has allowed us to pursue a more flexible and capital efficient manufacturing strategy. In the remainder of the year, we plan to continue to develop our unique cell-targeted lipid nanoparticle (ctLNP) system for systemic delivery to hepatocytes, as well as for other therapeutic areas such as the retina and vaccines.”
Article d’analyse Apr 20

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha Dec 30

Generation Bio: High-Risk, Medium-To-Low-Reward

Generation Bio is a preclinical-stage gene therapy company aiming to use non-viral delivery system to deliver DNA in vivo. The non-viral delivery system of choice is lipid nanoparticle, similar delivery vehicle the mRNA COVID vaccines are using. The big issue is, LNP will not help with nuclear translocation which is needed for DNA gene therapy to have decent efficacy. The recent preclinical update on their Hemophilia A program confirms the low efficacy issue of LNP-DNA, and therefore the stock is not a buy.
Article d’analyse Nov 11

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Article d’analyse Jul 28

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Article d’analyse Mar 08

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse Jan 14

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Potential Generation Bio Co. ( NASDAQ:GBIO ) shareholders may wish to note that the Independent Director, Charles...
Article d’analyse Dec 27

Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de GBIO ( $93.5M ) dépassent ses passifs à court terme ( $21.0M ).

Passif à long terme: Les actifs à court terme de GBIO ( $93.5M ) dépassent ses passifs à long terme ( $50.3M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: GBIO est sans dette.

Réduire la dette: GBIO n'a eu aucune dette au cours des 5 dernières années.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: GBIO dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: GBIO dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 4.1 % chaque année


Découvrir des entreprises saines

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/02/10 12:38
Cours de l'action en fin de journée2026/02/06 00:00
Les revenus2025/09/30
Revenus annuels2024/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Generation Bio Co. est couverte par 3 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Silvan TuerkcanCitizens JMP Securities, LLC
Brendan SmithTD Cowen
Raju PrasadWilliam Blair & Company L.L.C.